New targeted drug BAT8008 enters human testing for Hard-to-Treat cancers
NCT ID NCT05620017
First seen Feb 12, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This early-stage trial is testing a new drug called BAT8008 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target a protein called Trop2 found on many cancer cells. The main goals are to check safety, find the best dose, and see initial signs of tumor shrinkage. About 182 participants will receive the drug by infusion every two weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Affiliated Cancer Hospital of Chongqing University
RECRUITINGChongqing, Chongqing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, China
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BAT8008 (a Trop2-targeting antibody-drug conjugate)
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is too soon to know if the drug will be effective. Side effects may occur, and the drug may not work for all tumor types.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.